Biogen Inc (BIIB)

306.87
0.02 0.01
NASDAQ : Health Care
Prev Close 306.85
Day Low/High 0.00 / 0.00
52 Wk Low/High 223.02 / 333.65
Avg Volume 2.12M
Exchange NASDAQ
Shares Outstanding 219.12M
Market Cap 67.78B
EPS 15.40
P/E Ratio 21.85
Div & Yield N.A. (N.A)

Latest News

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Glaucoma Treatment Maker a $95M

Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan

The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.

Endo International Shares Climb on Earnings Beat

Endo International Shares Climb on Earnings Beat

Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.

Biogen Announces Bioverativ As Name Of New Hemophilia-Focused Company

Biogen Announces Bioverativ As Name Of New Hemophilia-Focused Company

Biogen (NASDAQ: BIIB) today announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017.

Allergan Doesn't Need Large M&A: CEO

Allergan Doesn't Need Large M&A: CEO

The botox maker's CEO Bret Saunders reiterates that Allergan will be focused on smaller deals and buybacks

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'

Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Biogen (BIIB) Stock Slides, Reportedly Not Pursuing Sale

Biogen (BIIB) Stock Slides, Reportedly Not Pursuing Sale

Biogen (BIIB) stock is lower this afternoon after Reuters reported that the company has no plans to sell itself.

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Deal rumors are deflating, but a takeover bid could reward holdouts.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Cramer: Does It Have to Be All About Oil?

Cramer: Does It Have to Be All About Oil?

That's a shaky basis for a rally.

Biogen (BIIB) Is Today's Perilous Reversal Stock

Biogen (BIIB) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Biogen (BIIB) as a "perilous reversal" (up big yesterday but down big today) candidate

Biogen Is a Takeover Target but Don't Ignore the Risks

Biogen Is a Takeover Target but Don't Ignore the Risks

The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.

Biogen Jumps as Merger Rumors Resurface

Biogen Jumps as Merger Rumors Resurface

Will Allergan buy Biogen? Will Merck? The rumors are pushing up Biogen's stock.

Biogen (BIIB) Stock Declines in After-Hours, Allergan Unlikely to Pursue Takeover

Biogen (BIIB) Stock Declines in After-Hours, Allergan Unlikely to Pursue Takeover

Biogen (BIIB) stock is retreating in after-hours trading on Tuesday as Allergan (AGN) reportedly is not likely to pursue a takeover bid of the company.

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

The companies were also the subject of merger rumors back in April.

CNBC's Tirrell Explains Why Biogen (BIIB) Is a Takeover Target

CNBC's Tirrell Explains Why Biogen (BIIB) Is a Takeover Target

CNBC's Meg Tirrell explained the events that led up to the takeover interest in Biogen (BIIB) today.

Biogen (BIIB) Marked As A Barbarian At The Gate

Biogen (BIIB) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Biogen (BIIB) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Biogen (BIIB) Stock Jumps, Receives Takeover Interest From Merck, Allergan

Biogen (BIIB) Stock Jumps, Receives Takeover Interest From Merck, Allergan

Biogen (BIIB) stock is spiking in late-afternoon trading on Tuesday as the company has reportedly drawn takeover interest from Merck (MRK) and Allergan (AGN).

Approach Biogen With Caution

Approach Biogen With Caution

The drug stock has soared sharply higher in recent weeks; how it behaves on a pullback will be key.

Biogen and Ionis See Boost From Clinical Drug Trial

Biogen and Ionis See Boost From Clinical Drug Trial

Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.

S&P 500, Dow Drop as Crude Closes at April Low

S&P 500, Dow Drop as Crude Closes at April Low

Crude oil was deadweight for Wall Street on Monday as continued worries over an international supply glut kept commodity traders bearish.

S&P 500, Dow Remain Lower as Crude Closes Just Above $40

S&P 500, Dow Remain Lower as Crude Closes Just Above $40

The S&P 500 and Dow Jones Industrial Average extend their declines by early afternoon Monday as crude oil prices threaten to break below $40.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the health services industry higher today.